Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Taps Quartet For R&D
by Rick Mullin
January 11, 2016
| A version of this story appeared in
Volume 94, Issue 2
Quartet Medicine and Merck & Co. have formed a research partnership based on Quartet’s pipeline of small-molecule drugs modulating the tetrahydrobiopterin (BH4) pathway. Quartet will receive $20 million, split equally between an up-front payment and milestone payments, to advance pain and inflammation treatment candidates to Phase II clinical trials. In return, Merck gets an exclusive option to purchase Quartet, in which case Quartet will receive an undisclosed option exercise payment and milestone payments of up to $575 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter